Contribution of a European ‐Prevalent Variant near CD83 and an East Asian–Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome‐Wide Association Study Meta‐Analyses

ConclusionGenetic analysis of tofacitinib-treated subjects with RA or PsO identified multiple loci associated with increased HZ risk. Prevalent variants near the immune-relevant genesCD83 andIL17RB in European and East Asian populations, respectively, may contribute to risk of HZ in tofacitinib-treated subjects.

Source: Arthritis and Rheumatology - May 28, 2021 Category: Rheumatology Authors: Nan Bing, Huanyu Zhou, Xing Chen, Tomohiro Hirose, Yuta Kochi, Yumi Tsuchida, Kazuyoshi Ishigaki, Shuji Sumitomo, Keishi Fujio, Baohong Zhang, Hernan Valdez, Michael S. Vincent, David Martin, James D. Clark Tags: Original Article Source Type: research